Sanofi clears key regulatory milestones, shares track European pharma peers

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 20:29.

Sanofi (FR0000120578) strengthens its position in neurology and immunology this week, as regulators in the European Union and Japan clear new indications, according to company statements and newswire reports. On Euronext Paris, the shares recently traded at around 73.5 euros, keeping the group in the Stoxx Europe 600 Health Care spotlight.

What the latest approvals cover

On June 23, Sanofi reported that the European Commission approved Cenrifki (tolebrutinib) as the first medicine in the EU specifically targeting disability progression in secondary progressive multiple sclerosis without relapses, following a positive opinion from the EMA’s CHMP, as summarized by MarketScreener and Dow Jones Newswires. The approval adds a differentiated BTK inhibitor to Sanofi’s neurology portfolio at a time when European payers scrutinize specialty drug budgets.

In parallel, Japan’s Ministry of Health, Labour, and Welfare granted marketing and manufacturing approval for Wayrilz (rilzabrutinib) for the treatment of immune thrombocytopenia, broadening Sanofi’s hematology and immunology reach in a key Asian market, according to a Marketscreener-based news summary. Both approvals arrive in the same week that the company signed a memorandum of understanding with Abu Dhabi’s Department of Health to explore a vaccine innovation center in the emirate.

How analysts and peers frame the stock

On the NYSE, the Sanofi American Depositary Shares (ticker SNY) last closed at 41.78 US dollars on June 22, 2026, with a market capitalization of roughly 99.6 billion US dollars, according to consolidated quote data on StockAnalysis. The same source compiles a consensus rating of "Buy" and an average analyst price target of 55.90 dollars, implying a double-digit percentage upside versus the latest close.

Within the European large-cap pharmaceuticals space, Sanofi trades alongside peers such as Novartis and Roche in the Stoxx Europe 600 Health Care and remains a core constituent of several income-focused portfolios, supported by a dividend yield above 4 percent based on a 1.76 dollar annual payout for the SNY ADRs, as indicated by analyst data aggregators. The low reported beta of around 0.28 underscores the comparatively muted volatility profile of the shares against the broader US and European equity benchmarks.

The products behind the approvals

Cenrifki (tolebrutinib) is described by Sanofi as a next-generation, brain-penetrant Bruton's tyrosine kinase inhibitor developed to slow disability progression in multiple sclerosis, with the EU approval specifically addressing secondary progressive disease without relapses, according to the company’s latest regulatory communication. Wayrilz (rilzabrutinib) targets immune thrombocytopenia by modulating B-cell and Fc receptor signaling, adding an oral treatment option for patients in Japan where unmet medical needs persist in chronic immune-mediated platelet disorders.

Where the stock trades today

The Sanofi shares (FR0000120578) traded on Euronext Paris at 73.47 euros as of 2026-06-23, 15:30, based on live data snapshots from MarketScreener and exchange feeds.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a solicitation to buy or sell securities, or a personal recommendation. Investors should conduct their own research and consider their individual financial situation and risk profile.